[go: up one dir, main page]

WO2003013605A1 - Remedes pour maladies prostatiques - Google Patents

Remedes pour maladies prostatiques Download PDF

Info

Publication number
WO2003013605A1
WO2003013605A1 PCT/JP2002/008016 JP0208016W WO03013605A1 WO 2003013605 A1 WO2003013605 A1 WO 2003013605A1 JP 0208016 W JP0208016 W JP 0208016W WO 03013605 A1 WO03013605 A1 WO 03013605A1
Authority
WO
WIPO (PCT)
Prior art keywords
prostatic
interactions
lpa
cells
epithelial cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/008016
Other languages
English (en)
Japanese (ja)
Inventor
Masahiro Furuno
Takayuki Naito
Yoshihisa Yamamoto
Junken Aoki
Hiroyuki Arai
Yoshiyuki Kakehi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of WO2003013605A1 publication Critical patent/WO2003013605A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne la prévention et le traitement de maladies prostatiques. Plus particulièrement, on a découvert que les causes et les mécanismes de l'apparition de maladies prostatiques sont étroitement associés à des interactions entre des récepteurs de LPA faisant office d'un ligand et les interactions entre diverses substances physiologiquement actives ainsi sécrétées à partir des cellules épithéliales prostatiques et des cellules interstitielles prostatiques ; que les cellules interstitielles prostatiques prolifèrent du fait desdites interactions ; et qu'une substance inhibant les interactions entre les récepteurs de LPA et la LPA inhibe la prolifération de cellules prostatiques. L'invention concerne des compositions médicinales basées sur lesdites découvertes, contenant, comme principe actif, une substance inhibant la transduction de signaux intracellulaires induite par des stimulus induits par le récepteur Edg-7 qui est l'un des récepteurs de LPA et est fréquemment exprimé dans des cellules épithéliales prostatiques. A l'aide desdites compositions, la transduction de signaux et la sécrétion des substances physiologiquement actives telles que susmentionnées sont inhibées. L'invention permet ainsi d'empêcher et/ou de traiter les maladies prostatiques.
PCT/JP2002/008016 2001-08-07 2002-08-06 Remedes pour maladies prostatiques Ceased WO2003013605A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001239306 2001-08-07
JP2001-239306 2001-08-07
JP2002-224215 2002-07-31
JP2002224215 2002-07-31

Publications (1)

Publication Number Publication Date
WO2003013605A1 true WO2003013605A1 (fr) 2003-02-20

Family

ID=26620108

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/008016 Ceased WO2003013605A1 (fr) 2001-08-07 2002-08-06 Remedes pour maladies prostatiques

Country Status (1)

Country Link
WO (1) WO2003013605A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517996B2 (en) 2003-08-05 2009-04-14 Ajinomoto Co., Inc. Azole compound

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0518769A1 (fr) * 1991-06-14 1992-12-16 Adir Et Compagnie Nouveaux dérivés de benzoate d'éthanolamine, leur procédé de préparation et les compositions pharmaceutiques les renfermant
EP0878479A2 (fr) * 1997-05-13 1998-11-18 Smithkline Beecham Corporation Récepteur couplé à la protéine G (HOFNH30)
WO1999067383A1 (fr) * 1998-06-22 1999-12-29 Japan Tobacco Inc. Nouvelle proteine receptrice couplee a la proteine g, adn correspondante et leur utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0518769A1 (fr) * 1991-06-14 1992-12-16 Adir Et Compagnie Nouveaux dérivés de benzoate d'éthanolamine, leur procédé de préparation et les compositions pharmaceutiques les renfermant
EP0878479A2 (fr) * 1997-05-13 1998-11-18 Smithkline Beecham Corporation Récepteur couplé à la protéine G (HOFNH30)
WO1999067383A1 (fr) * 1998-06-22 1999-12-29 Japan Tobacco Inc. Nouvelle proteine receptrice couplee a la proteine g, adn correspondante et leur utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BANDOH K., AOKI J. ET AL.: "Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid", J. BIOL. CHEM., vol. 274, no. 39, 1999, pages 27776 - 27785, XP000990175 *
FITZGERALD L.R. ET AL.: "Identification of an EDG7 variant, HOFNH30, a G-protein-coupled receptor for lysophosphatidic acid", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 273, no. 3, 2000, pages 805 - 810, XP002957397 *
IM D.S. ET AL.: "Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate", MOL. PHARMACOL., vol. 57, no. 4, 2000, pages 753 - 759, XP002957398 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517996B2 (en) 2003-08-05 2009-04-14 Ajinomoto Co., Inc. Azole compound

Similar Documents

Publication Publication Date Title
TW200510328A (en) 5-membered heterocycle-based p38 kinase inhibitors
IL172082A0 (en) Foamable pharmaceutical compositions and methods for treating a disorder
WO2008045228A3 (fr) Dispositifs médicaux munis de zones poreuses pour exposition ou délivrance contrôlées d'un agent thérapeutique
PL1635824T3 (pl) 5-Członowe heterocykliczne inhibitory P-38
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
WO2005041925A3 (fr) Compositions et formes posologiques permettant une absorption amelioree
EP2116245A3 (fr) combinaisons d'inhibiteurs de la kinase EGFR pour le traitement de désordres respiratoires et de l'appareil digestif
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
MXPA02010618A (es) Inhibidores de fosfatidilinositol 3-quinasa delta.
WO2003092580A3 (fr) Methodes et compositions pour le traitement des troubles du systeme nerveux central et du systeme nerveux peripherique et nouveaux composes associes
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
ATE311373T1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
WO2007049098A3 (fr) Formulations therapeutiques pour le traitement de maladies associees au beta-amyloide
WO2005034883A3 (fr) Procede de chauffage de blessures cutanees chez les mammiferes et composition correspondante
WO2005112633A3 (fr) Composes et compositions pour administration d’agents actifs
WO2001001972A3 (fr) ANTAGONISTES SELECTIFS DU RECEPTEUR iGluR5 UTILISES DANS LE TRAITEMENT DE LA MIGRAINE
WO2005016306A3 (fr) Administration reguliere de topiramate pendant une periode prolongee a formulation de dispersion amelioree
WO2004034975A3 (fr) Procede permettant de modifier le profil de liberation de compositions a liberation lente
WO2005046593A3 (fr) Methodes et compositions faisant appel a du thalidomide pour le traitement et pour la gestion de cancers et d'autres maladies
MY129668A (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
TW200509998A (en) Controlled release of highly soluble agents
WO2005020957A3 (fr) Administration progressive de topiramate sur une duree prolongee
WO2005004854A3 (fr) Utilisation de la betaine pour le traitement des arterites
BG106548A (en) Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP